EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access

GEMPAX, do we have another second-line option after mFOLFIRINOX in pancreatic cancer?

Kathleen Boyle, Kimberly J Perez

Annals of Translational Medicine · 2025-02 · 13 (1) · 9-9

DOI: 10.21037/atm-24-182 ↗

Kurz gefasst

Editorial in der Zeitschrift Annals of Translational Medicine, 2025-02. Verfasst von Kathleen Boyle und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Pancreatic adenocarcinoma (PDAC)gemcitabine (GEM)paclitaxel

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Harvard Medical School, Boston, MA, USA.

Zitieren

APA

Boyle, K., & Perez, K. J. (2025). GEMPAX, do we have another second-line option after mFOLFIRINOX in pancreatic cancer?. Annals of Translational Medicine, 13(1), 9-9. https://doi.org/10.21037/atm-24-182

Vancouver

Boyle K, Perez KJ. GEMPAX, do we have another second-line option after mFOLFIRINOX in pancreatic cancer?. Annals of Translational Medicine. 2025;13(1):9-9. doi:10.21037/atm-24-182

BibTeX
@article{Boyle2025,
  author = {Boyle, Kathleen and Perez, Kimberly J},
  title = {GEMPAX, do we have another second-line option after mFOLFIRINOX in pancreatic cancer?},
  journal = {Annals of Translational Medicine},
  year = {2025},
  volume = {13},
  number = {1},
  pages = {9--9},
  doi = {10.21037/atm-24-182}
}
Kostenlos starten →